Clinton's breakthrough drug committee: will it stifle new drug development?
作者信息
Gatty B
出版信息
Hosp Formul. 1993 Nov;28(11):946, 945.
PMID:10130236
Abstract
摘要
相似文献
1
Clinton's breakthrough drug committee: will it stifle new drug development?克林顿的突破性药物委员会：它会扼杀新药研发吗？
Hosp Formul. 1993 Nov;28(11):946, 945.
2
How will drug and device makers fare under Clinton's reform plan?在克林顿的改革计划下，药品和器械制造商的情况会怎样？
Mater Manag Health Care. 1993 Nov;2(11):18, 20.
3
Health care reform and the pharmaceutical industry.医疗保健改革与制药行业。
Health Care Manag. 1994 Aug;1(1):187-96.
4
The need for health care reform.医疗保健改革的必要性。
Health Syst Rev. 1994 May-Jun;27(3):5-6.
5
Price controls for drugs.药品价格管制
J Med Assoc Ga. 1995 Mar;84(3):135-6.
6
The visible hand. Clinton's health reform could alter prospects for millions of enterprises.看得见的手。克林顿的医疗改革可能会改变数百万企业的前景。
US News World Rep. 1993 Oct 4;115(13):78-9, 82-6.
7
Health care reform: pharmaceutical industry sees itself as 'whipping boy'.医疗保健改革：制药行业视自身为“替罪羊”。
Hosp Formul. 1993 Oct;28(10):872, 871.
8
Price controls in the pharmaceutical industry could hurt medical education.制药行业的价格管制可能会损害医学教育。
Nephrol News Issues. 1993 Jun;7(6):46-7.
9
Health care reform's price fight.医疗保健改革中的价格之争。
Natl J (Wash). 1994 Aug 13;26(33):1923-4.
10
CBO report refutes drug industry's fear of reform hurting R&D.
Mod Healthc. 1994 Jul 11;24(28):36.
Zotero 插件